New pill aims to stop pre-cancerous blood condition from turning deadly
NCT ID NCT07435636
Summary
This trial is testing whether a low-dose oral medication can control a high-risk blood cell condition called CCUS, which affects about 10% of people over 70 and can progress to blood cancers. Researchers will give 80 participants either the active drug combination or a placebo for 24 weeks to see if it reduces abnormal blood cells and improves blood counts. The goal is to develop a safe treatment that prevents progression to more serious diseases.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLONAL HEMATOPOIESIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Canberra Health Services
Canberra, Australian Capital Territory, 2605, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Prince of Wales Hospital
Randwick, New South Wales, 2031, Australia
Contact Phone: •••-•••-••••
-
Westmead Hospital
Westmead, New South Wales, 2145, Australia
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.